Zhang Yuchen, Zhang Haoliang, Lv Kangjia, Lin Xin, Chen Feng'e, Cao Hui, Chen Chong
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
National Clinical Research Center for Ophthalmic Diseases, Shanghai 200080, China.
Vaccines (Basel). 2025 Jul 7;13(7):733. doi: 10.3390/vaccines13070733.
: Retinal vascular occlusion (RVO) and retinal artery occlusion (RAO) have been reported as rare adverse events following COVID-19 vaccination, raising concerns about vaccine safety. This review synthesizes cohort and case-control studies assessing the association between COVID-19 vaccines and RVO/RAO, while exploring potential pathophysiological mechanisms. : We analyzed large-scale population-based studies from South Korea, Europe, and the TriNetX database, focusing on odds ratios (OR), hazard ratios (HR), and relative risks (RR) across mRNA and adenoviral vector vaccines. Pathological processes were hypothesized based on molecular and clinical evidence. : Studies investigating the association between COVID-19 vaccination and retinal vascular occlusion show conflicting results; some studies report no association (e.g., OR 0.93, 95% CI 0.60-1.45), others suggest reduced risk (e.g., OR 0.80, 95% CI 0.64-0.99), and one indicates increased risk over two years (HR 2.19, 95% CI 2.00-2.39). Adenoviral vector vaccines, particularly ChAdOx1, show higher RAO incidence in specific cohorts. Proposed mechanisms include vaccine-induced immune thrombotic thrombocytopenia (VITT) via anti-PF4 antibodies, spike protein-mediated endothelial dysfunction, and adjuvant-driven inflammation. : While causality remains unproven, temporal heterogeneity and vaccine type-specific risks warrant further investigation. Longitudinal studies with robust controls are needed to clarify these associations in the post-pandemic context.
视网膜血管阻塞(RVO)和视网膜动脉阻塞(RAO)已被报告为新冠病毒疫苗接种后的罕见不良事件,这引发了人们对疫苗安全性的担忧。本综述综合了队列研究和病例对照研究,评估新冠病毒疫苗与RVO/RAO之间的关联,同时探讨潜在的病理生理机制。我们分析了来自韩国、欧洲和TriNetX数据库的大规模基于人群的研究,重点关注mRNA疫苗和腺病毒载体疫苗的比值比(OR)、风险比(HR)和相对风险(RR)。根据分子和临床证据对病理过程进行了假设。研究新冠病毒疫苗接种与视网膜血管阻塞之间关联的研究结果相互矛盾;一些研究报告无关联(例如,OR 0.93,95%可信区间0.60-1.45),另一些研究表明风险降低(例如,OR 0.80,95%可信区间0.64-0.99),还有一项研究表明两年内风险增加(HR 2.19,95%可信区间2.00-2.39)。腺病毒载体疫苗,尤其是ChAdOx1,在特定队列中显示出较高的RAO发病率。提出的机制包括通过抗PF4抗体引起的疫苗诱导的免疫性血栓性血小板减少症(VITT)、刺突蛋白介导的内皮功能障碍和佐剂驱动的炎症。虽然因果关系尚未得到证实,但时间异质性和疫苗类型特异性风险值得进一步研究。需要进行有强有力对照的纵向研究,以在大流行后背景下阐明这些关联。